Showing results (101-110 of 160) with videos related to
Sort By:
Pageof 16
Targeted Oncology|February 23, 2022
Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid TumorsMatilda Xinwei Lee, Andrea L A Wong, Samuel Ow, et al.Yonsei Medical Journal|May 28, 2013
The impact of cigarette smoking on the frequency of and qualitative differences in KRAS mutations in Korean patients with lung adenocarcinomaHye Ryun Kim, Jung Ryun Ahn, Jin Gu Lee, et al.Cancer Treatment Reviews|August 16, 2024
Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscapeMichael Weller, Jordi Remon, Stefan Rieken, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 4, 2020
An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLCViola W Zhu, Yen-Ting Lin, Dong-Wan Kim, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 9, 2023
Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLCRoss A Soo, Jean-François Martini, Anthonie J van der Wekken, et al.Lung Cancer (Amsterdam, Netherlands)|April 28, 2026
Asia-Pacific practical consensus in the management of adverse events related to amivantamab-based therapies in non-small cell lung cancerRoss A Soo, Pablo Fernandez-Penas, Molly Li, et al.The Lancet. Oncology|November 1, 2019
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trialAlice T Shaw, Benjamin J Solomon, Rita Chiari, et al.Clinical Pharmacokinetics|December 11, 2023
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung CancerJoseph Chen, Alessandra Bearz, Dong-Wan Kim, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2023
Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 InsertionsZofia Piotrowska, Daniel Shao-Weng Tan, Egbert F Smit, et al.Cancer Cell|May 20, 2020
TERAVOLT: Thoracic Cancers International COVID-19 CollaborationJennifer G Whisenant, Annalisa Trama, Valter Torri, et al.Pageof 16